Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07405190 · ClinicalTrials.gov registry record · Phase 2
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT07405190: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT07405190 is a Phase 2 study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07405190, a Phase 2 study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to assess the efficacy of ivonescimab monotherapy in patients with advanced non-small cell lung cancer harboring actionable genomic alterations who have received prior targeted therapies and chemotherapy. This clinical trial also aims to assess the efficacy of ivonescimab plus carboplatin/pemetrexed chemotherapy in patients with advanced non-small cell lung cancer harboring actionable genomic alterations other than epidermal growth factor receptor mutations who have received prior targeted therapies but no chemotherapy. The main questions it aims to answer are: * Will ivonescimab alone or together with carboplatin/pemetrexed chemotherapy shrink tumors in the clinical trial's patients? * Will ivonescimab alone or together with carboplatin/pemetrexed chemotherapy effectively influence if the patients' cancer grows, how long the treatment takes to start working, how long the treatment keeps working after it first starts to help, how long the treatment keeps the cancer from getting worse, and overall survival of patients? * How many patients receiving ivonescimab alone or together with carboplatin/pemetrexed chemotherapy will experience treatment-emergent, treatment-related, immune-related, and especially interesting side effects? Patients receiving ivonescimab alone will receive an intravenous infusion of ivonescimab every 3 weeks for up to 24 months. Patients receiving ivonescimab together with carboplatin/pemetrexed chemotherapy will receive separate intravenous infusions of ivonescimab, pemetrexed, and carboplatin every 3 weeks for 4 cycles (each cycle is 21 days). These patients will continue to receive infusions of ivonescimab and pemetrexed every 3 weeks for up to 24 total months.
Interventions
- DRUG Ivonescimab
- DRUG carboplatin
- DRUG pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2026-08-04 |
| Est. Completion | 2029-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07405190
The ClinicalTrials.gov registry entry for NCT07405190 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ivonescimab is the first listed.
NCT07405190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07405190 about?
NCT07405190 is a clinical study titled "Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC". The goal of this clinical trial is to assess the efficacy of ivonescimab monotherapy in patients with advanced non-small cell lung cancer harboring actionable genomic alterations who have received prior targeted therapies and chemotherapy. This clinical trial also aims to assess the efficacy of ivon...
What is the current status of trial NCT07405190?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2026-08-04. Estimated completion is 2029-03-01.
What interventions are being tested in trial NCT07405190?
The interventions under investigation include: Ivonescimab (DRUG), carboplatin (DRUG), pemetrexed (DRUG).
Who is sponsoring clinical trial NCT07405190?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.